Academe Learn
CBME Curriculum Preview

Page 22 of 22

IM28.1-26 | Obstructive Airway Diseases — PBL Case

CLINICAL SETTING

Dr Ananya is a final-year resident presenting a new admission to the General Medicine ward of a government teaching hospital in Chennai. The patient is Mr Murugesan, a 57-year-old man who has worked at a brick-kiln in the outskirts of Chennai for the past 22 years. He is a current smoker (25 pack-years) and lives with his wife and two adult children in a two-room house where cooking is done on a wood-burning stove. He has no formal education. He is admitted today via casualty with a 5-day history of worsening breathlessness, increased cough with yellowish-green sputum, and inability to walk to the toilet without stopping. He says: 'This happens every winter. The last time they put me on a drip here, I was fine after 3 days and sent home. I stopped the inhaler because it was expensive.' His wife adds: 'He has been like this — slowly getting worse — for 10 years. We thought it was just age and smoking. Nobody ever explained what was wrong with him.' On arrival: RR 26/min, SpO2 87% on room air, pulse 104/min, BP 138/78, temperature 37.8°C, afebrile peripherally. He is using accessory muscles. You can hear expiratory wheeze from across the bed.

Trigger 1: The Initial Assessment: More Than Just an Exacerbation

Dr Ananya commences the examination. On inspection: barrel-shaped chest, pursed-lip breathing, prolonged expiratory phase. Trachea central. Percussion: hyperresonant bilaterally. Auscultation: reduced air entry bilaterally, diffuse expiratory wheeze, no crackles. No finger clubbing. No ankle oedema. She orders an ABG on room air: pH 7.32, PaCO2 7.1 kPa (53 mmHg), PaO2 6.8 kPa (51 mmHg), HCO3 26 mmol/L, SpO2 88%. She applies a 28% Venturi mask. CXR shows hyperinflated lung fields, flattened diaphragms, increased AP diameter, and no consolidation. She notes there is no prior spirometry on his records, though he has had 4 previous admissions with similar presentations. The intern asks: 'Should we do spirometry now?'

DISCUSSION POINTS

  • What does Mr Murugesan's clinical examination pattern (barrel chest, hyperresonance, pursed-lip breathing, prolonged expiration, reduced air entry) indicate, and what is the underlying pathophysiology driving each finding?
  • Interpret the ABG: classify the acid-base disorder, identify the type of respiratory failure, and explain why a 28% Venturi mask (controlled FiO2) is used rather than high-flow oxygen at 10 L/min.
  • The intern asks whether to do spirometry now — during an acute exacerbation. What is the appropriate answer? When is spirometry indicated for diagnosis, and can it be safely performed during an acute episode?
Click to reveal Trigger 2: Medical History: 22 Years at the Kiln (discuss previous trigger first!)

Trigger 2: Medical History: 22 Years at the Kiln

Dr Ananya takes a full history while the acute management is initiated. Mr Murugesan describes his first symptoms at age 47: initially morning cough with sputum, then slowly progressive breathlessness on exertion. Now he stops after walking 50 metres on flat ground (MRC grade 3). He has 3-4 infective exacerbations per year. He lives near the kiln and is exposed to silica dust, coal ash, and coal smoke 8-10 hours daily. At home, the wood-burning stove is in the main living room. He smokes 10 bidis/day; he has tried to stop twice. 'When I don't smoke, I feel even more nervous — I can't sleep.' He has never been told his spirometry results. His brother, also a smoker, died at age 62 of a 'lung problem'. When his current inhalers are reviewed, he has a salbutamol MDI but admits he had not been shown how to use it correctly. A community health worker present in the ward notes: 'His employer told us he gets bonus pay for not taking sick leave — so he avoids coming to hospital until it is very bad.'

DISCUSSION POINTS

  • What occupational and environmental exposures in Mr Murugesan's history contribute to the development and exacerbation of COPD, and how does each interact with cigarette smoke to accelerate lung damage? Apply relevant IM28.6 and IM28.7 concepts.
  • Using the 5As framework for smoking cessation counselling, plan how you would counsel Mr Murugesan. Specifically address the barriers he has identified: nicotine dependence symptoms (anxiety, insomnia on cessation), bidi use as culturally normalised, and the economic pressure that delays healthcare-seeking.
  • Assess Mr Murugesan's inhaler use and formulate a practical counselling plan for correct pMDI technique that accounts for his education level and likely compliance barriers.
Click to reveal Trigger 3: Day 2: Spirometry, GOLD Staging, and the Treatment Decision (discuss previous trigger first!)

Trigger 3: Day 2: Spirometry, GOLD Staging, and the Treatment Decision

Mr Murugesan improves on 28% Venturi oxygen (SpO2 rises to 91%), nebulised salbutamol 2.5 mg 4-hourly, ipratropium 500 mcg 6-hourly, IV hydrocortisone 100 mg 6-hourly, and oral amoxicillin-clavulanate (given purulent sputum and CRP 48 mg/L). He is afebrile and RR is 18/min by the afternoon of day 2. Dr Ananya performs post-bronchodilator spirometry on day 4: FEV1 0.9 L (32% predicted for age/height), FVC 2.7 L, FEV1/FVC 0.33. No significant reversibility (FEV1 increase after salbutamol = 90 mL, 10%). Blood eosinophil count: 180 cells/microL. She discusses his GOLD group classification and plans his discharge medication. She is considering whether to add an ICS to his LABA+LAMA regimen. The ward pharmacist reports that his previous inhaler (salbutamol only) was not covered under the government scheme; he will now be given a free fixed-dose LABA+LAMA device.

DISCUSSION POINTS

  • Apply GOLD 2023 staging: what is Mr Murugesan's GOLD spirometric grade (FEV1 % predicted) and his GOLD group (ABE) based on symptoms and exacerbation history? Justify your answer with the specific criteria.
  • Using the GOLD 2023 treatment algorithm, construct his discharge pharmacotherapy plan: which drug class(es) are recommended, and should ICS be added given his blood eosinophil count of 180 cells/microL? Explain the threshold for ICS addition in COPD.
  • What specific discharge instructions and follow-up plan would reduce his risk of re-admission? Include: medication adherence strategies, PEFR monitoring plan, an action plan for early exacerbation recognition, influenza and pneumococcal vaccination schedule.
Click to reveal Trigger 4: The Systemic Burden: Family, Work, and What Cannot Be Changed (discuss previous trigger first!)

Trigger 4: The Systemic Burden: Family, Work, and What Cannot Be Changed

Before discharge, Dr Ananya sits with Mr Murugesan and his wife. His wife is tearful: 'He cannot carry a sack of bricks anymore. He used to be the strongest man at the kiln. His employer says if he cannot do the physical work, they will replace him. We have loans — the rent, the children's college fees. If he stops working, we cannot manage.' Mr Murugesan says quietly: 'I know I should stop the kiln work. But what else can I do? I am 57, no education, no other skill. The doctor in my village told me to stop smoking and change my job 5 years ago. I tried to stop smoking three times. I could not. I stopped going to that doctor because he just told me things I already knew I should do.' He adds: 'My lungs are already damaged — what is the point of stopping now?' Dr Ananya is asked to write a referral letter to the employer's occupational health officer and to advise the patient on realistic options for improving his future health.

DISCUSSION POINTS

  • Mr Murugesan says 'What is the point of stopping smoking now — my lungs are already damaged?' How would you respond to this accurately and empathically, drawing on the evidence that smoking cessation benefits persist even in established COPD?
  • How should Dr Ananya counsel Mr Murugesan and his wife on the realistic impact of COPD on occupational capacity, financial stability, and family roles — balancing honest prognosis with preservation of hope and agency? Refer to IM28.23 and IM28.25.
  • Write the key points of a referral letter to the brick-kiln's occupational health officer recommending workplace modifications to reduce Mr Murugesan's further exposure. Use the hierarchy of controls (elimination, substitution, engineering, administrative, PPE) to structure your recommendations.

Group Task Assignments

  • Using Mr Murugesan's history, construct a complete problem list and an integrated management plan covering: (a) acute exacerbation treatment; (b) stable-phase maintenance therapy per GOLD 2023; (c) smoking cessation plan using 5As; (d) occupational exposure reduction; (e) vaccinations; (f) a discharge action plan the patient can follow at home with limited literacy.
  • Design a structured patient education card (maximum 10 bullet points, simple language, no medical jargon) that explains: what COPD is, how to use the LABA+LAMA inhaler correctly, when to seek emergency help, and one specific action the patient can take today to slow disease progression.
  • Debate the following proposition: 'In a resource-limited setting like Mr Murugesan's, the physician's primary responsibility is to the individual patient's acute illness — occupational and systemic factors are beyond the physician's scope.' What are the arguments for and against? What does IM28.24 expect of a physician in this situation?
  • Calculate Mr Murugesan's approximate COPD progression risk. He is 57, smokes 10 bidis/day, FEV1 32% predicted, 3-4 exacerbations/year, ongoing silica exposure. Using published evidence, rank the interventions in order of impact on 5-year mortality: smoking cessation, LTOT, LABA+LAMA, pulmonary rehabilitation, ICS addition.

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [IM28.4] What is the pathophysiology of hypoxia and hypercapnia in COPD, and why does CO2 retention emerge in severe disease when it is not present in moderate disease?
  2. [IM28.11] What are the GOLD spirometric criteria for COPD diagnosis and grading? How do the GOLD 2023 ABE groups classify patients, and what determines group E membership?
  3. [IM28.18] What are the components of acute exacerbation management in COPD, and when is NIV indicated? What are the correct oxygen targets for a CO2-retaining COPD patient?
  4. [IM28.19] What are the LTOT criteria (PaO2 threshold, minimum hours per day), and how is oxygen flow titrated in a hypercapnic COPD patient to avoid suppressing hypoxic drive?
  5. [IM28.20] What is the 5As framework for smoking cessation, and how does it address the specific barriers of nicotine dependence, bidi use, and patient beliefs that cessation is pointless in advanced disease?
  6. [IM28.24] What are the occupational causes and preventive hierarchy for COPD in brick-kiln and silica-exposure settings, and what is the physician's role in occupational health advocacy?